4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cardiovascular complications in inflammatory bowel disease.

      , , 1
      Current drug targets

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Over the past years, a growing number of studies have indicated that patients suffering from inflammatory bowel disease (IBD) have an increased risk of developing cardiovascular disease. Both are chronic inflammatory diseases and share certain pathophysiological mechanisms that may influence each other. High levels of cytokines, C-reactive protein (CRP), and homocysteine in IBD patients may lead to endothelial dysfunction, an early sign of atherosclerosis. IBD patients, in general, do not show the typical risk factors for cardiovascular disease but changes in lipid profiles similar to the ones seen in cardiovascular events have been reported recently. Higher levels of coagulation factors frequently occur in IBD which may predispose to arterial thromboembolic events. Finally, the gut itself may have an impact on atherogenesis during IBD through its microbiota. Microbial products are released from the inflamed mucosa into the circulation through a leaky barrier. The induced rise in proinflammatory cytokines could contribute to endothelial damage, artherosclerosis and cardiovascular events. Although large retrospective studies favor a link between IBD and cardiovascular diseases, the mechanisms behind still remain to be determined.

          Related collections

          Author and article information

          Journal
          Curr Drug Targets
          Current drug targets
          1873-5592
          1389-4501
          2015
          : 16
          : 3
          Affiliations
          [1 ] Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Austria. rudolf.schicho@medunigraz.at.
          Article
          CDT-EPUB-64948 EMS62256
          10.2174/1389450116666150202161500
          4366573
          25642719
          8ea0c9a1-c301-454e-bf82-e8ad3377aa41
          History

          Comments

          Comment on this article